Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
O. Leeuwenkamp, J. Smith-Palmer, R. Ortiz, A. Werner, W. Valentine, M. Blachier & T. Walter. (2020) Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. Journal of Medical Economics 23:12, pages 1534-1541.
Read now
Read now
Articles from other publishers (20)
Shiraz Halloush, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mathias Calamia, Hala Halawah, Mavis Obeng-Kusi, Martin Hoyle, Omar Rashdan, Jim Koeller & Ivo Abraham. (2023) Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. Annals of Pharmacotherapy, pages 106002802211468.
Crossref
Crossref
Yuki Takumoto, Yuriko Sasahara, Hiroto Narimatsu, Tatsunori Murata & Manabu Akazawa. (2022) Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Economics Review 12:1.
Crossref
Crossref
Paul Gissen, Nicola Specchio, Andrew Olaye, Mohit Jain, Thomas Butt, Wrik Ghosh, Benjamin Ruban-Fell, Annabel Griffiths, Charlotte Camp, Zlatko Sisic, Christoph Schwering, Eva Wibbeler, Marina Trivisano, Laura Lee, Miriam Nickel, Amanda Mortensen & Angela Schulz. (2021) Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2). Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
J. Smith-Palmer, O. R. Leeuwenkamp, J. Virk & N. Reed. (2021) Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer 21:1.
Crossref
Crossref
Elsa M. Ronde, Charlotte M. Heidsma, Anne M. Eskes, Josefine E. Schopman & Elisabeth J. M. Nieveen van Dijkum. (2021) Health‐related quality of life and treatment effects in patients with well‐differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta‐analysis. European Journal of Cancer Care 30:6.
Crossref
Crossref
Marije E. Hagendijk, Simon van der Schans, Cornelis Boersma, Maarten J. Postma & Simon van der Pol. (2021) Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. The European Journal of Health Economics 22:6, pages 991-999.
Crossref
Crossref
Michael Iskedjian, Edward De Vol, Mahmoud Elshenawy & Shouki Bazarbashi. (2020) Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia. JCO Global Oncology:6, pages 1609-1616.
Crossref
Crossref
Jayne Palmer & Oscar R Leeuwenkamp. (2020)
Cost-effectiveness of lutetium (
177
Lu) oxodotreotide
vs
everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
. World Journal of Clinical Cases 8:20, pages 4793-4806.
Crossref
Crossref
James I. Barnes, John K. Lin, Divya Gupta, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert & Pamela L. Kunz. (2020) Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network 18:9, pages 1200-1209.
Crossref
Crossref
John K. Ramage, Pankaj Punia, Olusola Faluyi, Andrea Frilling, Tim Meyer, Ruby Saharan & Juan W. Valle. (2019) Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). Neuroendocrinology 108:4, pages 317-327.
Crossref
Crossref
Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage & Martin Hoyle. (2018) Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technology Assessment 22:49, pages 1-326.
Crossref
Crossref
Monika Wagner, Dima Samaha, Jesus Cuervo, Harshila Patel, Marta Martinez, William M. O’Neil & Paula Jimenez-Fonseca. (2018) Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient–Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context. Advances in Therapy 35:8, pages 1215-1231.
Crossref
Crossref
Monika Wagner, Dima Samaha, Hanane Khoury, William M. O’Neil, Louis Lavoie, Liga Bennetts, Danielle Badgley, Sylvie Gabriel, Anthony Berthon, James Dolan, Matthew H. Kulke & Mireille Goetghebeur. (2017) Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. Advances in Therapy 35:1, pages 81-99.
Crossref
Crossref
Andrea Young, Devidas Menon, Jackie Street, Walla Al-Hertani & Tania Stafinski. (2017) Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet Journal of Rare Diseases 12:1.
Crossref
Crossref
Yang Meng, Grant McCarthy, Anthony Berthon & Jerome Dinet. (2017) Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study. Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Anna OhDang M. TranLeann C. McDowellDor KeyvaniJay Andrew BarcelonOscar MerinoLeslie Wilson. (2017) Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. Journal of Managed Care & Specialty Pharmacy 23:6, pages 653-664.
Crossref
Crossref
Marianne Pavel, Nicole Unger, Ivan Borbath, Sergio Ricci, Tsann-Long Hwang, Thomas Brechenmacher, Jinhee Park, Fabian Herbst, Jennifer L. Beaumont & Oliver Bechter. (2016) Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. Targeted Oncology 11:5, pages 667-675.
Crossref
Crossref
Jean Lachaine, Karine Mathurin, Stéphane Barakat & Andre C. Schuh. (2015) Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematological Oncology 33:4, pages 229-238.
Crossref
Crossref
Karoline Freeman, Martin Connock, Ewen Cummins, Tara Gurung, Sian Taylor-Phillips, Rachel Court, Mark Saunders, Aileen Clarke & Paul Sutcliffe. (2015) Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technology Assessment 19:91, pages 1-322.
Crossref
Crossref
Jean Lachaine, Karine Mathurin, Stéphane Barakat & Stephen Couban. (2015) Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology 95:3, pages 218-229.
Crossref
Crossref